Vistagen Reports Positive Data from PALISADE-3 Study of Fasedienol in Social Anxiety Disorder
Key Highlights for Investors
- Positive Preliminary Data: Vistagen announced promising preliminary results from the open-label extension (OLE) of its PALISADE-3 Phase 3 study for fasedienol nasal spray, targeting the acute treatment of social anxiety disorder (SAD).
- Strong Safety Profile: Fasedienol, administered as-needed for up to 12 months, was well-tolerated with no new drug-related safety concerns. Discontinuation due to adverse events was low (2.6%), and no discontinuations were attributed to fasedienol. Most treatment-emergent adverse events (TEAEs) were mild or moderate. The most common TEAEs were headache (10.9%) and upper respiratory infection (11.4%). Importantly, there were no serious adverse events related to the drug.
- Clinically Relevant Efficacy: Over four months, patients demonstrated sustained and clinically meaningful improvements in social anxiety symptoms, as measured by both clinician-administered and patient-reported scales (LSAS and SPIN).
- Regulatory and Pipeline Implications: PALISADE-4, a pivotal Phase 3 trial, is on track for topline data in Q2 2026. Positive results from PALISADE-4, in combination with existing data, could support a potential New Drug Application (NDA) submission to the FDA for fasedienol in SAD.
- Market Opportunity: Fasedienol is positioned as a rapid-onset, as-needed, intranasal therapy with a differentiated safety profile, potentially offering a new therapeutic option in a large, underserved market.
Detailed Report
Study Overview and Results
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company, reported preliminary positive data from the ongoing OLE portion of its PALISADE-3 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder. The OLE enrolled 341 patients who could use 3.2 µg fasedienol nasal spray as needed, up to six times daily, in real-world anxiety-provoking situations for up to 12 months.
- Fasedienol was well-tolerated, with a discontinuation rate due to adverse events of just 2.6% (9 out of 341). Notably, none of these discontinuations were attributed to the drug itself.
- Over 95% of TEAEs were mild or moderate. The only TEAEs reported in more than 5% of subjects were headache (10.9%) and upper respiratory infection (11.4%).
- No serious adverse events related to fasedienol were observed. No safety signals of concern emerged from laboratory tests, ECGs, physical examinations, or vital signs.
Efficacy Outcomes
The OLE explored changes from baseline in two validated measures:
-
Liebowitz Social Anxiety Scale (LSAS):
- Baseline mean score: 99.2 (very severe social anxiety).
- Month 1: 16.3-point mean improvement (38% had ≥20-point improvement).
- Month 2: 22.4-point mean improvement (49% had ≥20-point improvement).
- Month 3: 24.1-point mean improvement (54% had ≥20-point improvement).
- Month 4: 25.4-point mean improvement (56% had ≥20-point improvement).
-
Social Phobia Inventory (SPIN):
- Baseline mean score: 48.7 (severe social anxiety).
- Month 1: 7.9-point mean improvement (35% had ≥10-point improvement).
- Month 4: 12.4-point mean improvement (55% had ≥10-point improvement).
Improvements were noted in both the fear and avoidance components of social anxiety. Notably, even subjects who did not initially respond in the clinic-based public speaking challenge saw meaningful benefit during the OLE.
Clinical and Commercial Implications
- The sustained improvement and robust safety profile seen in the OLE support the potential clinical meaningfulness of fasedienol for SAD. These findings are consistent with previous long-term safety and efficacy studies, indicating that as-needed, self-administered fasedienol can reduce fear, anxiety, and avoidance in daily life.
- The ongoing PALISADE-4 Phase 3 trial and a repeat dose exploratory Phase 2 trial are expected to yield topline results in Q2 and Q3 2026, respectively. If PALISADE-4 is successful, these data could provide the substantial evidence needed for a potential NDA submission.
- Fasedienol is being developed as a novel, rapid-onset, non-systemic, intranasal treatment for SAD. Its mechanism, focusing on nose-to-brain neurocircuitry without the need for blood or brain absorption, could differentiate it from existing pharmacological options and represents a significant commercial opportunity in neuropsychiatry.
Potential Price-Sensitive Information
- Positive interim data from the OLE portion of PALISADE-3, including safety and efficacy signals, is likely to be viewed favorably by investors and could be price-sensitive, especially as it supports the ongoing potential of fasedienol in a large market.
- The upcoming topline results from PALISADE-4 and the exploratory Repeat Dose Study are significant near-term catalysts that could further impact share price depending on outcomes.
- Vistagen’s stated path toward NDA submission, contingent on further successful data, places the company in a potentially pivotal position within the next 12 months.
About Vistagen and Next Steps
Vistagen is a late clinical-stage company pioneering a new class of rapid-onset, nose-to-brain, neurocircuitry-focused intranasal therapeutics called pherines. The company’s pipeline, including fasedienol, targets unmet needs in social anxiety disorder, major depressive disorder, and vasomotor symptoms due to menopause.
Investors should closely monitor the upcoming PALISADE-4 and Repeat Dose Study results, as they represent key value inflection points. Further, the consistency of efficacy across studies and the differentiated safety profile may attract strategic interest or partnership opportunities.
Disclaimer
This article is based on preliminary clinical data and statements provided by Vistagen Therapeutics, Inc. Forward-looking statements are subject to significant risks and uncertainties, including clinical trial outcomes, regulatory actions, and commercial viability. This is not investment advice; investors should perform their own due diligence and consult professional advisors before making investment decisions.
